Aldeyra Therapeutics begins enrolment in allergic conjunctivitis study

Statistics show that allergic conjunctivitis affects more than one billion people globally. Credit: Daniel Roberts from Pixabay.



  • Aldeyra Therapeutics begins enrolment in Phase III allergic conjunctivitis study